Home

This is an old revision of the document!


Presentation - Olmesartan medoxomil & treatment of autoimmune disease

Type: Conference presentation
Presenter: Dr. Greg Blaney
Conference: 7th International Congress on Autoimmunity
Location: Ljubljana, Slovenia
Date: May 2010

Abstract

Recent research highlights the importance of VDRThe Vitamin D Receptor. A nuclear receptor located throughout the body that plays a key role in the innate immune response. integrity and responsiveness on innate immune function. VDR knock out mice show both an increased frequency and severity of autoimmune disease and reduced ability to cope with bacterial infection and persistence. We have found that autoimmune disease in humans is associated with elevated levels of 1,25 OH Vitamin D indicating VDR resistance. Co-morbid conditions such as colitis, sinusitis, vasculitis and recurrent infections, reflecting intracellular or biofilm A structured community of microorganisms encapsulated within a self-developed protective matrix and living together. bacterial persistence, have been found by ourselves and others in autoimmune diseases. In silicoExperiment technique performed on computer or via computer emulation. modeling and clinical observation show that olmesartan medoxomil, an angiotensin receptor blocker, acts as a VDR agonistA substance such as olmesartan (Benicar) or 1,25-D which activates the Vitamin D Receptor and transcribes the genes necessary for a proper innate immune response.. Selected patients with significant and advanced autoimmune disease, including inflammatory arthropathy, autoimmuneA condition or disease thought to arise from an overactive immune response of the body against substances and tissues normally present in the body thyroiditis, ankylosing spondylitis, sarcoidosis, were treated with olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. at dosing levels sufficient to activate the VDR along with bacteriostatic antibiotics at sub-inhibitory dose levels. During treatment, temporary exacerbation of symptoms and worsening of clinical markers were seen reflecting immune response. Physical manifestations included inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. and swelling of joints, dermatitis, central and peripheral nervous system dysfunction, fever and fatigue. Laboratory changes included reduction in red and white blood cells, platelets; elevation in serum potassium, creatinine; and reduction in eGFR. After sufficient time of treatment, positive therapeutic responses that manifested included reversal of late-stage autoimmune conditions including carotid artery calcification, inflammatory joint disease, neuropathy, and osteoporosis. In addition normalization of clinical markers such as CRP,SED rate, kidney function were observed.

home/publications/benediktsson_autoimmunity_2010.1276533303.txt.gz · Last modified: 06.14.2010 by paulalbert
© 2015, Autoimmunity Research Foundation. All Rights Reserved.